Approved Hospital Formulary
QR Code Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:

dabigatran etexilate

dabigatran etexilate
Brand names: Pradaxa
Form Strength
CAPSULE, ORAL 75 mg; 150 mg


Additional Information:

Anticoagulation Therapy Management: Policy 900.3207

Clinical Guidelines:

Initiation/Dosing: Anticoagulation selection for patients with non-valvular atrial fibrillation. See Guideline 900.5008

Initiation/Other: Direct Oral Anticoagulant Use for Venous Thromboembolism, see Protocol 900.5206

Transitioning: Warfarin transition (to or from rivaroxaban): See Guideline 900.5863

Surgery: Timing of Neuraxial Anesthesia and Anticoagulation: see Guideline 900.5681

Surgery: Periprocedural Management of Anticoagulation therapy: See Protocol 900.5011

Reversal: Reversal in bleeding patients or for emergent surgery: See Reversal Guideline 900.5010

Reversal: Idarucizumab is the available antidote for dabigatran.  Supply may be limited, call your inpatient pharmacist for information.

Do Not Crush: Bioavailability increases by 75% when the pellets are taken without the capsule shell.


Last updated: Jan. 17, 2022







This site is intended for the staff of Legacy Health.
While others may view accessible pages, Legacy Health makes no warranty, express or implied,
as to the use of this information outside of Legacy Health.